- Home
- FSP vs ALDX Comparison
FSP vs ALDX Comparison
Compare FSP & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSP
- ALDX
- Stock Information
- Founded
- FSP 1981
- ALDX 2004
- Country
- FSP United States
- ALDX United States
- Employees
- FSP N/A
- ALDX N/A
- Industry
- FSP Real Estate Investment Trusts
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- FSP Real Estate
- ALDX Health Care
- Exchange
- FSP Nasdaq
- ALDX Nasdaq
- Market Cap
- FSP 159.5M
- ALDX 160.8M
- IPO Year
- FSP N/A
- ALDX 2014
- Fundamental
- Price
- FSP $1.70
- ALDX $3.05
- Analyst Decision
- FSP
- ALDX Strong Buy
- Analyst Count
- FSP 0
- ALDX 2
- Target Price
- FSP N/A
- ALDX $9.50
- AVG Volume (30 Days)
- FSP 345.2K
- ALDX 769.8K
- Earning Date
- FSP 07-29-2025
- ALDX 07-31-2025
- Dividend Yield
- FSP 2.35%
- ALDX N/A
- EPS Growth
- FSP N/A
- ALDX N/A
- EPS
- FSP N/A
- ALDX N/A
- Revenue
- FSP $115,994,000.00
- ALDX N/A
- Revenue This Year
- FSP $4.36
- ALDX N/A
- Revenue Next Year
- FSP $0.81
- ALDX N/A
- P/E Ratio
- FSP N/A
- ALDX N/A
- Revenue Growth
- FSP N/A
- ALDX N/A
- 52 Week Low
- FSP $1.36
- ALDX $1.14
- 52 Week High
- FSP $2.21
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- FSP 47.28
- ALDX 61.89
- Support Level
- FSP $1.67
- ALDX $2.60
- Resistance Level
- FSP $1.83
- ALDX $3.24
- Average True Range (ATR)
- FSP 0.05
- ALDX 0.22
- MACD
- FSP -0.02
- ALDX 0.09
- Stochastic Oscillator
- FSP 23.53
- ALDX 80.93
About FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.